Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Ulthera System Treatment

PreclinicalSmall molecule

Ulthera System Treatment is one of 2 small molecule programs targeting Hyperhidrosis. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperhidrosisActive, not recruiting

HyperhidrosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Hyperhidrosis

#DrugCompanyPhaseTrials

Oxytrol

Ulthera System Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hyperhidrosis1 trial

Feasibility Study: Safety and Efficacy of the Ulthera® System for Treatment of Axillary Hyperhidrosis

Completed·UUlthera, Inc·N/A·NCT01713673·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ulthera System Treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ulthera System Treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ulthera System Treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ulthera, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUlthera, Inc

Related News